A detailed history of Ronald Blue Trust, Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Ronald Blue Trust, Inc. holds 27 shares of HALO stock, worth $1,273. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27
Previous 11 145.45%
Holding current value
$1,273
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

BUY
$51.3 - $64.42 $820 - $1,030
16 Added 145.45%
27 $1,000
Q2 2024

Jul 18, 2024

BUY
$37.81 - $52.4 $415 - $576
11 New
11 $0
Q2 2022

Aug 09, 2022

BUY
$37.35 - $48.3 $1,718 - $2,221
46 New
46 $2,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.57B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Ronald Blue Trust, Inc. Portfolio

Follow Ronald Blue Trust, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ronald Blue Trust, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ronald Blue Trust, Inc. with notifications on news.